2016 has arrived, but was 2015 a good year for you, your company and your industry?
In this special feature, we look back at the year to identify the highs and lows of 2015 – the big stories and important issues that shaped the industry here in the UK and further afield.
Among other issues, we examine the ongoing mania for
mergers, the rise of biosimilars, the deepening focus on the patient and the
ever-pressing issue of patient access to pharma’s life-changing medicines.
On the way, we consider the relationship between pharma and
physicians in the first year of disclosure, pressing public health challenges
including antimicrobial resistance and the funding and pricing of cancer drugs.
At PharmaTimes, we like to think we have our finger on the
pulse of the key events and issues of the industry, but just to make sure, we
reached out to a wide range of industry experts to ask them what issues stand
out for them from the year just gone.